Background: Observational studies have suggested that sodium-glucose cotransporter 2 inhibitors (SGLT2i) are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation ...
Background: Cardiovascular disease (CVD) prevalence is rising among younger women in the US. Hypertensive disorders of pregnancy (HDP) are early indicators of cardiovascular risk, yet it remains ...
Background: Patients with prior ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events (MACE). The benefits of achieving very low levels of low-density ...
Background: Cardiovascular disease (CVD) causes more than 50% of deaths in patients with advanced chronic kidney disease (CKD). Clinical studies suggest that kidney-derived factors contribute to CVD ...
CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they ...
BACKGROUND: A 3-dimensional hyperboloid model has been proposed to characterize ventricular tachycardia (VT) circuitry. We ...
Cardiovascular and metabolic health are influenced by the circadian system, which regulates 24-hour rhythms across numerous physiologic processes. Disruptions to circadian rhythmicity can adversely ...
Background: Little correlation exists between the burden of ischemia and severity of angina in patients with stable coronary artery disease. This placebo-controlled, n-of-1 study investigated the ...
The 2025 AHA/ACC High Blood Pressure Guideline reflects the latest recommendations and advancements in hypertension research and clinical practice. This curated collection of commentaries and ...
Deoxycorticosterone acetate-salt hypertension (DOCASH) and sham rats were prepared following previously established methods 1; vasoconstriction and western blot experiments followed standard protocols ...
JAK inhibitors are used as anti-inflammatory agents, or to curb autoimmune diseases, hence the antifibrotic effects observed here could be secondary to reduced immune cell activity, although, as ...